Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05092360 |
|---|---|
| Brief Title: | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7) |
| First Submitted : | October 13, 2021 |
| First Submitted that Met QC Criteria : | October 13, 2021 |
| First Posted : | October 25, 2021 |
| Last Update Submitted that Met QC Criteria : | April 19, 2024 |
| Last Update Posted : | April 23, 2024 |